Deleuran, M. et al. 2021. Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use. Acta Dermato-Venereologica. 101, 7 (Jul. 2021), adv00504. DOI:https://doi.org/10.2340/00015555-3848.